CRSP - CRISPR Therapeutics AG

QQQ $ 446.25 $ -12.35 (-2.68 %)

DIA $ 404.28 $ -3.99 (-0.98 %)

SPY $ 539.90 $ -9.25 (-1.68 %)

TLT $ 99.49 $ -0.01 (-0.01 %)

GLD $ 230.65 $ -1.72 (-0.74 %)

Previous Close

$ 44.62

Open

Bid

$ 44.18 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 37.55 - $ 91.10

Volume

1,143,930

Average Volume

Market Cap

3.8B

Beta (5Y Monthly)

$ 1.05

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-05-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	02-21-2024	12-31-2023	10-K
4	11-06-2023	09-30-2023	10-Q
5	08-07-2023	06-30-2023	10-Q
6	05-08-2023	03-31-2023	10-Q
7	02-21-2023	12-31-2022	10-K
8	11-01-2022	09-30-2022	10-Q
9	08-08-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	02-15-2022	12-31-2021	10-K
12	11-03-2021	09-30-2021	10-Q
13	07-29-2021	06-30-2021	10-Q
14	04-27-2021	03-31-2021	10-Q
15	02-16-2021	12-31-2020	10-K
16	10-28-2020	09-30-2020	10-Q
17	07-27-2020	06-30-2020	10-Q
18	04-28-2020	03-31-2020	10-Q
19	02-12-2020	12-31-2019	10-K
20	10-28-2019	09-30-2019	10-Q
21	07-29-2019	06-30-2019	10-Q
22	04-29-2019	03-31-2019	10-Q
23	02-25-2019	12-31-2018	10-K
24	11-07-2018	09-30-2018	10-Q
25	08-07-2018	06-30-2018	10-Q
26	05-08-2018	03-31-2018	10-Q
27	03-08-2018	12-31-2017	10-K
28	11-08-2017	09-30-2017	10-Q
29	08-10-2017	06-30-2017	10-Q
30	05-11-2017	03-31-2017	10-Q
31	03-10-2017	12-31-2016	10-K
32	11-22-2016	09-30-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Truist Securities Maintains Buy on CRISPR ...
08/12/2024 13:01:00

Truist Securities analyst Joon Lee maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $...

Cantor Fitzgerald Reiterates Neutral on CR...
08/08/2024 14:31:30

Cantor Fitzgerald analyst Eric Schmidt reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral.

jim-cramer-this-energy-stock-is-a-buy-stay-away-from-dexcom

Jim Cramer: This Energy Stock Is A Buy, St...
08/08/2024 13:29:44

The "Mad Money" host says Dexcom had "a real bad miss... they still really haven't fully explained why that is....

Barclays Maintains Equal-Weight on CRISPR ...
08/06/2024 13:32:12

Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from ...

RBC Capital Maintains Sector Perform on CR...
08/06/2024 12:56:14

RBC Capital analyst Luca Issi maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Sector Perform and lowers the price target ...

Stifel Maintains Hold on CRISPR Therapeuti...
08/06/2024 11:26:28

Stifel analyst Benjamin Burnett maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Hold and lowers the price target from $60...

Chardan Capital Maintains Buy on CRISPR Th...
08/06/2024 10:44:31

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target f...

Needham Maintains Buy on CRISPR Therapeuti...
08/06/2024 10:12:30

Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $88 to $84.

CRISPR Therapeutics Q2 2024 Adj EPS $(1.49...
08/05/2024 20:07:05

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.49) per share which beat the analyst consensus estimate of $...

cathie-wood-touts-palantir-coinbase-and-roku-as-arks-flagship-fund-shifts-focus-from-mag-6-amid-whiff-of-lower-interest-rates

Cathie Wood Touts Palantir, Coinbase And R...
07/11/2024 11:15:15

In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fu...

Guggenheim Assumes CRISPR Therapeutics at ...
06/28/2024 11:56:49

Guggenheim analyst Debjit Chattopadhyay assumes CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating.

Needham Reiterates Buy on CRISPR Therapeut...
06/27/2024 09:35:14

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $88 price target.

Intellia Therapeutics Presents Data On Red...
06/25/2024 19:32:54

First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 ...

Piper Sandler Reiterates Overweight on CRI...
06/17/2024 17:13:14

Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and maintains $105 pric...

Needham Reiterates Buy on CRISPR Therapeut...
06/17/2024 09:36:07

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $88 price target.

Citigroup Maintains Buy on CRISPR Therapeu...
05/23/2024 17:27:52

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from ...

CRISPR Therapeutics' Julianne Bruno, M.B.A...
05/23/2024 12:17:01

-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer-ZUG, Swi...

Oppenheimer Maintains Outperform on CRISPR...
05/10/2024 16:47:42

Oppenheimer analyst Jay Olson maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from...

JMP Securities Reiterates Market Outperfor...
05/09/2024 18:24:32

JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $...

Wells Fargo Maintains Equal-Weight on CRIS...
05/09/2024 16:04:05

Wells Fargo analyst Yanan Zhu maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target fr...